Extended Data Fig. 7: Subgroup analysis of change in HbA1c from baseline to week 40 according to baseline oral anti-hyperglycemic medication use and enrolment in China versus out of China. | Nature Medicine

Extended Data Fig. 7: Subgroup analysis of change in HbA1c from baseline to week 40 according to baseline oral anti-hyperglycemic medication use and enrolment in China versus out of China.

From: Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial

Extended Data Fig. 7

ETD and CIs in HbA1c at week 40 were estimated using an MMRM without missing-value imputation in the patients who received at least 1 dose of study drug (5 mg, N = 230; 10 mg, N = 228; 15 mg, N = 229; insulin glargine, N = 220); all statistical tests were two sided at a significance level of 0.05 and no adjustments were made for multiplicity. Data presented are LSMean. Error bars indicate 95% CI. P values represent treatment-by-subgroup interaction at week 40. ETD, estimated treatment difference; CI, confidence interval; CHN, China; HbA1c, glycated hemoglobin; LSMean, least-square mean; MMRM, mixed model for repeated measures; N, number of patients who were randomized and received at least 1 dose of study drug; OAM, oral anti-hyperglycemic medication; OCHN, out of China; SU, sulphonylurea; TZP, tirzepatide.

Back to article page